珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
2020年12月10日 11:18:22来源:作者:

Boehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk & Kollegen
Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments
Boehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world

INGELHEIM, Germany & OCHSENHAUSEN, Germany -- (BUSINESS WIRE) --

Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.

“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”

Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.

Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.

“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”

The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/

CONTACT:

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

责任编辑: admin

看新闻,关注新闻

网易网友:強顏歡笑ソ
评论:闭上眼睛,我看到了我的前途

搜狐网友:﹎拿命再愛√
评论:为何现在的女人上面穿羽绒服下面却穿丝袜.""问得好!因为鲜奶要保温、火腿要冷藏

其它网友:Cold-blooded 凉薄
评论:命是爸妈给的,珍惜点;路是自己走的,小心点。

腾讯网友:︶別致微笑ゞ
评论:过着八戒的生活,却想要悟空的身材。

本网网友:我的就是你的
评论:我是个特别的人,我是个平凡的人,所以我是个特别平凡的人

凤凰网友:THOMAS 《死亡诗社》
评论:警察说:"你不知道开车不让打电话吗?"我一脸疑惑的说:"我没打电话呀?.....我发短信来着!"

猫扑网友:厮守°- Michae
评论:再多各自牛逼的时光,也比不上一起傻逼的岁月!

天猫网友:℡說好不見面
评论:我们这个年龄,更多的是练爱而不是恋爱。

天涯网友:心不亡wenod∕
评论:不为人知的猥琐是闷骚,无伤大雅的猥琐是情调。

百度网友:ゆ.舌尖腥咸
评论:上联:该吃吃、该喝喝、有事别往心里搁。下联:泡泡澡、看看表、舒服一秒是一秒。横批:不能白活。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!